BioCentury | Jan 4, 2020
Targets & Mechanisms

SIGLECs go from homing beacons to next-generation checkpoints

Propelled by growing understanding of their biology, and an expression pattern that goes well beyond T cells, SIGLEC proteins are rising as the next set of checkpoint targets to challenge PD-1. The sugar-binding proteins could...
BioCentury | Feb 16, 2019
Product Development

ADCs’ inflection point

Industry is writing a new rule book for antibody-drug conjugates that could take the modality beyond the one-size-fits-all approach that has limited its success. By 2Q20, late-stage data from at least four ADCs testing new...
BioCentury | Jan 5, 2019
Finance

Ready to launch

  The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record...
BioCentury | Jul 13, 2018
Finance

Curating Abingworth

With a narrower set of investment strategies and a diversified LP base for its latest fund, Abingworth is seeking double digit returns from the $315 million Bioventures VII. Abingworth’s Kurt von Emster told BioCentury the...
BC Extra | Jan 11, 2018
Company News

Pfizer's Barrett named CEO of Novartis Oncology

Novartis AG (NYSE:NVS; SIX:NOVN) hired Elizabeth Barrett as CEO of Novartis Oncology, effective Feb. 1. She succeeds Bruno Strigini, who is retiring for personal reasons (see BioCentury Extra, Dec. 15, 2017) . Barrett is global president...
BioCentury | Jan 6, 2018
Finance

Burgeoning bellwethers

  The miserable performance of large cap biotechs last quarter is likely to be a boon for small- and mid-cap players this year, in more ways than one. Buysiders spent most of 2017 focusing to...
BioCentury | Dec 9, 2017
Product Development

Multimodal meeting

This year’s clinical abstracts at the American Society of Hematology meeting hint at how newer treatment modalities -- cell therapies in cancer and gene therapies in hematology -- will branch out into new indications and...
BioCentury | Oct 6, 2017
Finance

Bargain shopping

With all companies valued over $1 billion increasing a median of at least 16.8% in 1H17, investors went bargain shopping in the $500-$999 million tier in 3Q17. The group outperformed all other market cap bands,...
BC Week In Review | Aug 18, 2017
Clinical News

FDA approves Pfizer's Besponsa to treat ALL

FDA approved a BLA from Pfizer Inc. (NYSE:PFE) for Besponsa inotuzumab ozogamicin (CMC-544, PF-5208773) to treat adults with relapsed or refractory B cell precursor acute lymphoblastic leukemia. Besponsa’s label includes a boxed warning for hepatotoxicity,...
BC Extra | Aug 17, 2017
Company News

FDA approves Pfizer's Besponsa for ALL

FDA approved a BLA from Pfizer Inc. (NYSE:PFE) for Besponsa inotuzumab ozogamicin to treat adults with relapsed or refractory B cell precursor acute lymphoblastic leukemia. Besponsa’s label includes a boxed warning for hepatotoxicity, including hepatic...
Items per page:
1 - 10 of 35